Tee Labs Incubatee | Full-Life Technologies Closes Over RMB 1 Billion Financing

SHANGHAI & BRUSSELS — May 19, 2026 — Full-Life Technologies (“Full-Life”), a fully integrated, clinical-stage global radiopharmaceutical therapy company, announced today the closing of over RMB 1 billion in financing, comprising approximately RMB 750 million in Series D equity financing and a RMB 270 million debt facility. The financing round was led by Vivo Capital, with participation from Full-Life’s strategic partner SK Biopharmaceuticals, alongside Chengwei Capital, Sequoia China, Jiachen Capital, Yunion Healthcare Fund, Plaisance Capital, Sky9 Capital, TSG Capital, and several other premier institutional investors. Since its inception in 2021, Full-Life has secured nearly USD 350 million in cumulative equity and debt financing.

Proceeds from this financing round will be deployed to accelerate the clinical development of the company’s therapeutic pipelines. Key priorities include:[225Ac]Ac-FL-020: A potential best-in-class radioligand drug candidate for prostate cancer;[225Ac]Ac-FL-261: A potential first-in-class radiopharmaceutical targeting multiple solid tumor indications. By the end of 2026, Full-Life anticipates advancing three highly differentiated clinical-stage programs, all generated from its proprietary UniRDC™ discovery platform. In addition, the funds will support the commissioning of GMP-grade Actinium-225 (225Ac) radioisotope production at the company’s state-of-the-art manufacturing facility in Belgium.

About Full-Life

Full-Life Technologies (“Full-Life”) is a privately held, fully integrated, clinical-stage global radiopharmaceutical therapy company with operational headquarters and facilities in Belgium and China.

Centered unswervingly on patients worldwide, Full-Life is dedicated to building an end-to-end, full-value-chain radiopharmaceutical enterprise encompassing discovery, development, production, and commercialization. By spearheading cutting-edge innovative research, the company aims to resolve fundamental bottlenecks currently confronting radiopharmaceuticals and advance the next paradigm of targeted cancer therapies. The Full-Life leadership comprises high-performing entrepreneurs and seasoned scientists with proven track records across life sciences, radioisotope research, and clinical development.

About Tee Labs

Tee Labs is an international incubator and innovation community co-founded by seasoned entrepreneurs and venture capitalists, dedicated to advancing pioneering frontiers in medicine—including novel drug R&D, diagnostics, and personalized medicine powered by artificial intelligence and digital solutions.
We provide comprehensive support covering laboratory infrastructure, corporate functions, integrated supply chain and service channels, and venture capital, deeply empowering early-stage founding teams and accelerating company R&D cycles. The facilities are fully outfitted with foundational, general-purpose laboratory instrumentation alongside a shared equipment platform, substantially curtailing the startup phase for workspace and equipment procurement so that founders can focus entirely on core R&D milestones.
Currently, Tee Labs features approximately 2,600 square meters of incubation space, including 1,500 square meters of dedicated laboratory facilities covering chemistry, molecular biology, cell culture, microbial/bacterial culture, and Biosafety Level 2 (BSL-2) laboratories. These versatile, multi-type laboratory suites accommodate diverse research pipelines, providing early-stage ventures with the rare advantage of housing multidisciplinary teams within a single cohesive workspace.